Syndax and Merck Announce First Patients Dosed in Phase 1b/2 Clinical Trial of Entinostat and KEYTRUDA®
Dateline City:
WALTHAM, Mass. and KENILWORTH, N.J.
Clinical trial to assess safety and efficacy of immuno-oncology combination in patients with advanced NSCLC or melanoma
WALTHAM, Mass. and KENILWORTH, N.J. – Syndax Pharmaceuticals, Inc. and Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced the dosing of the first patients in the Phase 1b/2 clinical trial of Syndax’s entinostat in combination with Merck’s anti-PD-1 therapy KEYTRUDA® (pembrolizumab) in patients with non-small cell lung cancer (NSCLC) or melanoma.
Language:
English
read more
Source: Merck.com - Research and Development News - Category: Pharmaceuticals Tags: Oncology Newsroom Prescription Medicine News Research and Development News Corporate News Latest News Source Type: news
More News: Cancer | Cancer & Oncology | Clinical Trials | Lung Cancer | Melanoma | Merck | Non-Small Cell Lung Cancer | Pharmaceuticals | Skin Cancer